Wall Street Zen Upgrades Medifast Stock to 'Hold'

The weight-loss company's shares get a rating boost after previous 'sell' recommendation.

Mar. 22, 2026 at 7:24am

Got story updates? Submit your updates here. ›

Wall Street Zen has upgraded its rating on Medifast (NYSE:MED) shares from 'sell' to 'hold' in a new research note. The upgrade comes after the specialty retailer posted better-than-expected quarterly results, with revenue and earnings exceeding analyst estimates. Several other research firms have also recently weighed in on Medifast, with mixed ratings and price targets.

Why it matters

Medifast's stock performance and analyst coverage are closely watched by investors, as the company's weight-loss and wellness products and services are an important part of the growing health and nutrition market. The rating upgrade from Wall Street Zen could signal a shift in sentiment around the company's prospects.

The details

In its latest research note, Wall Street Zen cited Medifast's improved financial results as the reason for upgrading the stock to a 'hold' rating. The company reported Q4 2025 earnings per share of -$0.55, beating the consensus estimate of -$0.76. Revenue also topped expectations, coming in at $75.1 million. Medifast provides a range of meal replacement products, snacks, supplements and coaching programs under its OPTAVIA brand, targeting the weight-loss and metabolic health market.

  • Medifast reported Q4 2025 results on February 17, 2026.
  • Wall Street Zen published its research note and rating upgrade on March 22, 2026.

The players

Medifast, Inc.

A health and wellness company that specializes in clinically supported weight-loss, weight-management and healthy living products and services. The company markets its OPTAVIA brand of meal replacements, snacks, supplements and coaching programs directly to consumers.

Wall Street Zen

A research firm that provides analysis and ratings on publicly traded companies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

The rating upgrade for Medifast's stock reflects the company's improved financial performance, which could signal a shift in sentiment around its prospects in the weight-loss and wellness market. However, the mixed analyst coverage and ratings suggest the company still faces some challenges as it navigates the competitive landscape.